Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Celanese Highlights Safe and Effective Drug Delivery Applications of EVA at CPhI Worldwide Conference

Celanese Corporation
Posted on: 29 Sep 16

Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will highlight innovative drug delivery applications of ethylene vinyl acetate (EVA) at the 2016 CPhI Worldwide Conference October 4-6 in Barcelona, Spain.

Celanese will be sharing technical and application-specific information with customers and conference attendees about its broad medical portfolio, specifically highlighting the company’s VitalDose® EVA product in emerging pharmaceutical drug delivery applications, including implants for treatment of eye disease, retroviral infection, addiction, and other novel applications.

“Controlled-release drug delivery has always presented considerable challenges to developers and formulators, such as drug loading, device size, and long-term sustained drug release,” said Susan Rahe, global business director of the Celanese EVA polymers business. “VitalDose® EVA offers a safe and effective controlled release solution and is an inert thermoplastic that is expanding design possibilities for our customers with its customizable drug release properties.”

VitalDose® EVA as a controlled release excipient is developed for a wide variety of pharmaceutical products with varying routes of administration, including ophthalmic, intraoral, intravaginal, subcutaneous and transdermal. At the 2016 CPhI Worldwide Conference, Celanese will demonstrate how VitalDose® EVA can be used as a proven, safe and reliable controlled release excipient to solve fundamental drug delivery problems including patient compliance and frequency of dosage.

Celanese material experts will exhibit the innovative controlled release pharmaceutical copolymer VitalDose® EVA at booth number 4C96SSP. For more information about Celanese’s controlled release pharmaceutical EVA polymer, VitalDose® EVA, visit

On-booth meetings are available to schedule by contacting Celanese via email at

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our two complementary business cores, Acetyl Chain and Materials Solutions, use the full breadth of Celanese’s global chemistry, technology and business expertise to create value for our customers and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of $5.7 billion. For more information about Celanese and our product offerings, visit or our blog at .

All registered trademarks are owned by Celanese International Corporation or its affiliates.

Forward-Looking Statements

This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or its customers will realize these benefits or that these expectations will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

View source version on

Business Wire

Last updated on: 29/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.